Table II.
Biomarker value of miR-126 in the diagnosis and prognosis of lung cancer.
| A, Diagnosis | ||||||
|---|---|---|---|---|---|---|
| Methods using miR-126 as a diagnostic biomarker | Source | Specificity (%) | Sensitivity (%) | AUC (%) | Clinical stage | (Refs.) |
| Single | Serum | 84.00 | 96.40 | 87.40 | I–IV stage of lung cancer NSCLC metastasis | (55) |
| Single | Serum plasma | 78.00 | 79.00 | 90.00 | I–II stage of lung cancer | (56) |
| miR-222/miR-126 | Serum | 70.00 | 80.00 | 66.00 | Asbestos-related NSCLC | (57) |
| Single | Serum exosomes | – | – | – | I–II stage of lung cancer | (58) |
| Multiple miRNAs/miR-126 | Serum plasma | 87.00 | 87.00 | 94.00 | I–II stage of lung cancer | (56) |
| CEA/miR-126 | Serum exosomes | 100.00 | 81.20 | 96.50 | 0-IIIB stage of lung cancer | (59) |
| CEA/miR-126 | Serum exosomes | 92.50 | 88.50 | 97.50 | 0-I stage of lung cancer | (59) |
| Single, multiple miRNAs/miR-126 | Sputum | 90.00 | 90.00 | 93.10 | I–IV stage of lung cancer | (61) |
| Exosomal | Tissue | – | – | – | I–II stage of lung cancer | (14) |
| B, Prognosis | ||||||
| Methods using miR-126 as a prognostic biomarker | Source | DFS HRs (95% CIs) | PFS HRs (95% CIs) | OS HRs (95% CIs) | Clinical stage | (Refs.) |
| Single | Plasma | 1.867 (1.39–2.51) | – | 1.706 (1.22–2.39) | I–III stage of lung cancer | (66) |
| Single | Tissue | – | – | 2.27 (0.83–6.23) | I–IV stage of lung cancer | (67) |
| Single | Tissue | – | 0.10 (0.04–0.21) | 0.14 (0.06–0.31) | II–IV stage of lung cancer | (68) |
| Drosha/miR-126 | Tissue | – | – | – | I–III stage of lung cancer | (69) |
| let-7b/miR-126 | Tissue | – | 0.05 (0.02–0.14) | 0.05 (0.02–0.16) | II–IV stage of lung cancer | (68) |
AUC, area under the curve; NSCLC, non-small cell lung cancer; CEA, carcinoembryonic antigen; DFS, disease-free survival; HRs, Hazard ratios; CIs, confidence intervals; PFS, progression-free survival; OS, overall survival; Drosha, intranuclear miRNA processing enzyme Drosha; miRNA, microRNA.